Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Xencor Inc
(NQ:
XNCR
)
21.47
+0.65 (+3.12%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 13, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Xencor Inc
< Previous
1
2
3
Next >
Xencor to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023
February 16, 2023
From
Xencor, Inc.
Via
Business Wire
Xencor to Present at the SVB Securities Global Biopharma Conference
February 07, 2023
From
Xencor, Inc.
Via
Business Wire
3 Small-Cap Biopharma Stocks that Could See Big Growth in 2023
January 13, 2023
Health care stocks are trying to make a comeback and these three small-cap biopharma companies are leading the charge in some ways.
Via
MarketBeat
Xencor Highlights 2023 Corporate Priorities and Provides Portfolio Updates
January 09, 2023
From
Xencor, Inc.
Via
Business Wire
Xencor to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
Xencor, Inc.
Via
Business Wire
Xencor Presents Data from Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin Lymphoma at the American Society of Hematology Annual Meeting
December 12, 2022
From
Xencor, Inc.
Via
Business Wire
Xencor to Present at Upcoming Investor Conferences
November 10, 2022
From
Xencor, Inc.
Via
Business Wire
Xencor Presents Early Clinical Data from Combination Study of Vudalimab and New Data from Multiple Preclinical-stage XmAb® Programs at the SITC Annual Meeting
November 10, 2022
From
Xencor, Inc.
Via
Business Wire
Xencor Reports Third Quarter 2022 Financial Results
November 07, 2022
From
Xencor, Inc.
Via
Business Wire
Xencor’s IL2-Fc Cytokine, XmAb®564, is Well-tolerated and Selectively Expands Regulatory T Cells in Phase 1a Clinical Study
November 07, 2022
From
Xencor, Inc.
Via
Business Wire
Xencor to Present New Clinical Data from the Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin’s Lymphoma at the American Society of Hematology Annual Meeting
November 03, 2022
From
Xencor, Inc.
Via
Business Wire
Xencor to Host Third Quarter 2022 Financial Results Webcast and Conference Call on November 7, 2022
October 31, 2022
From
Xencor, Inc.
Via
Business Wire
Xencor to Present Seven Posters on Multiple Clinical Trials and Research-stage Programs at the SITC Annual Meeting
October 05, 2022
From
Xencor, Inc.
Via
Business Wire
Xencor Appoints Nancy Valente, M.D., to Board of Directors
September 09, 2022
From
Xencor, Inc.
Via
Business Wire
Xencor Reports Second Quarter 2022 Financial Results
August 03, 2022
From
Xencor, Inc.
Via
Business Wire
Xencor to Host Second Quarter 2022 Financial Results Webcast and Conference Call on August 3, 2022
July 27, 2022
From
Xencor, Inc.
Via
Business Wire
Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid Tumors
May 26, 2022
From
Xencor, Inc.
Via
Business Wire
Xencor Reports First Quarter 2022 Financial Results
May 05, 2022
From
Xencor, Inc.
Via
Business Wire
Xencor to Host First Quarter 2022 Financial Results Webcast and Conference Call on May 5, 2022
April 28, 2022
From
Xencor, Inc.
Via
Business Wire
Xencor Presents Data from Multiple Preclinical XmAb® Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022
April 08, 2022
From
Xencor, Inc.
Via
Business Wire
Xencor Reports Fourth Quarter and Full Year 2021 Financial Results
February 23, 2022
From
Xencor, Inc.
Via
Business Wire
Xencor to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 23, 2022
February 16, 2022
From
Xencor, Inc.
Via
Business Wire
Xencor to Present at Upcoming Investor Conferences
February 02, 2022
From
Xencor, Inc.
Via
Business Wire
Xencor Highlights 2022 Corporate Priorities and Portfolio Milestones
January 11, 2022
From
Xencor, Inc.
Via
Business Wire
Xencor to Present at the H.C. Wainwright Bioconnect Virtual Conference
January 06, 2022
From
Xencor, Inc.
Via
Business Wire
Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting
December 12, 2021
From
Xencor, Inc.
Via
Business Wire
Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor
November 21, 2021
From
Xencor, Inc.
Via
Business Wire
Xencor to Present at Upcoming Investor Conferences
November 19, 2021
From
Xencor, Inc.
Via
Business Wire
Xencor Presents Updated Data from the Phase 1 Study of Vudalimab, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual Meeting
November 12, 2021
From
Xencor, Inc.
Via
Business Wire
Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody Programs and IL-12 Cytokine, XmAb662, at the SITC Annual Meeting
November 12, 2021
From
Xencor, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.